Remove Compliance Remove Cosmetics Remove Life Science Remove Marketing
article thumbnail

Hyman, Phelps & McNamara, P.C. Takes Top Honors in Two Prestigious Categories in 2023 LMG Life Sciences Awards

FDA Law Blog

is pleased to announce it took top honors in two categories in the 2023 LMG Life Sciences Awards, which recognize the best life science practitioners and firms over the past 12 months from the United States, Canada, and Europe. life sciences industry. WASHINGTON, DC — Hyman, Phelps & McNamara, P.C.

article thumbnail

ACI To Host Multiple Events Featuring HP&M Speakers – Discounts Available to FDA Law Blog Readers

FDA Law Blog

The American Conference Institute (“ACI”) will be hosting a series of go-to forums on critical topics including novel therapeutics, cosmetics/personal care products and Paragraph IV disputes. Claud will be featured at the Legal, Regulatory, and Compliance Forum on Cosmetics & Personal Care Products in New York, NY.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

To help ensure compliance, it is advisable for companies to establish procedures to assess and verify IT security of social media and digital channels, and to review and monitor company activities, content, and materials. Therefore, companies are encouraged to establish a methodology for calculating fair market value rates.

article thumbnail

Florida approved to import Canadian prescription drugs

Pharma in Brief

Section 804 Importation Programs On October 1, 2020, the FDA published a rule entitled Importation of Prescription Drugs (the US Importation Rule ) to implement Section 804 of the Food, Drug, and Cosmetic Act. Biologics, controlled substances, and certain other drugs are not eligible for importation. 01.014.13).

Drugs 52
article thumbnail

Pharma in Brief’s 2023 Year in Review and Trends for 2024

Pharma in Brief

Changes in Canada’s pricing and market access regimes This year saw major developments in the drug price and reimbursement space, including at the Patented Medicine Prices Review Board ( PMPRB ), the pan-Canadian Pharmaceutical Alliance ( pCPA ), and the Canadian Agency for Drugs and Technologies in Health ( CADTH ).

article thumbnail

Considerations for Mobile Health Technology Developers: Part 2

pharmaphorum

The FDA regulates software that meets the definition of a medical device in section 201(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Criteria for regulation. The FDA interprets “pattern” to refer to multiple, sequential, or repeated measurements of a signal or from a signal acquisition system. Criterion 2.